McMaster University, Hamilton, Ontario, Canada.
McMaster University, Hamilton, Ontario, Canada.
Health Policy. 2020 Jan;124(1):7-11. doi: 10.1016/j.healthpol.2019.10.006. Epub 2019 Nov 4.
Canada is the only Universal Health Insurance country in the OECD without universal insurance for outpatient prescription drugs, a situation generally perceived as unfair and inefficient. In June 2018, the federal government launched an Advisory Council on the Implementation of National Pharmacare, to report in 2019 on the best strategy to implement a national Pharmacare program that would provide all Canadians access to affordable outpatient prescription drugs. The Council was asked to consider three options: a universal public plan for all Canadians; a public catastrophic insurance plan that would kick off once spending on prescription drugs reaches a given threshold; and a more modest patching of existing gaps, providing coverage to those who are not eligible to any form of insurance. Beyond the relative consensus around the ideas that gaps in coverage should be filled to make drugs affordable to all, and that the costs of drugs are too high in Canada, the Council faces the challenge of addressing three underlying issues: 1) what amount of income redistribution will result from each of the three options; 2) how much savings would the implementation of a single payer generate? 3) what role restricting a national formulary would play in achieving those savings, and what would be the political consequences of narrowing the formulary?
加拿大是经合组织(OECD)中唯一没有全民门诊处方药保险的全民医保国家,这种情况普遍被认为不公平且效率低下。2018 年 6 月,联邦政府成立了国家药品实施顾问委员会,该委员会需在 2019 年报告实施国家药品计划的最佳策略,该计划将使所有加拿大人都能负担得起门诊处方药的费用。该委员会被要求考虑以下三个选择:为所有加拿大人提供一个全民公共计划;一旦处方药支出达到给定门槛,就启动公共灾难性保险计划;以及对现有缺口进行适度修补,为那些没有资格获得任何形式保险的人提供保险。除了对以下观点达成相对共识外,即应填补保险覆盖范围的缺口以使所有药物都能负担得起,以及加拿大的药品成本过高,该委员会还面临着解决以下三个基本问题的挑战:1)三种选择中会产生多少收入再分配;2)单一支付方的实施将节省多少费用?3)限制国家处方集在实现这些节省方面的作用,以及缩小处方集的政治后果是什么?